Purpose: Frozen gloves (FG) are effective in preventing docetaxel-induced nail toxicity (DNT), but uncomfortable.The preventive effect of FG for DNT was compared using a standard (-25 to-30℃) or more comfortable (-10 to20℃) preparation.Methods: Breast cancer patients receiving docetaxel were eligible.Each patient wore an FG (prepared at-10 to-20℃ for 90 min) for 60 min without replacement on the right hand.The left hand was protected by standard methods (FG prepared at-25 to-30℃ overnight and worn for 90 min with replacement at 45 min).The primary endpoint was DNT occurrence at 5 months.Secondary endpoints included docetaxel exposure [cumulative dose and area under the blood concentration time curve (AUC)] until DNT occurrence and discomfort from FG.The pharmacokinetics of docetaxel was assessed.Results: From 23 patients enrolled between December 2006 and June 2010, seven who received docetaxel for less than 5 months were excluded from evaluation.The median accumulated docetaxel dose was 700 mg/m2 (340-1430 mg/m2).Within 5 months of FG use, none developed protocol-defined DNT in either hand.Two patients (13%) developed DNT at 7.2 and 7.3 months, respectively, both at-10 to-20℃.In the control hand (-25 to-30℃), discomfort occurred in 92% of the cycles, compared to 15% in the experimental hand (-10 to-20℃).Five patients (22%) experienced pain at-25 to-30℃, but none did at-10 to-20℃.The degree of docetaxel exposure was not related to DNT occurrence in our study.Conclusion: A convenient preparation of FG at-10 to-20℃ is almost as effective as a standard preparation at-25 to-30℃, with significantly less discomfort.